Skip to main content

Table 3 Responses to survey questions regarding willingness to participate in clinical trials including various treatments and procedures

From: Attitudes toward clinical trials across the Alzheimer’s disease spectrum

Trial design elements Diagnostic group Likelihood of participation
Very unlikely (score = 1–2) Neutral (score = 3–5) Very likely (score = 6–7)
Approved CN 6 (16.2%) 19 (51.4%) 12 (32.4%)
MCI 2 (6.25%) 12 (37.5%) 18 (56.3%)
Dementia 0 (0.00%) 5 (22.7%) 17 (77.3%)
Experimental CN 11 (29.7%) 21 (56.8%) 5 (13.5%)
MCI 4 (12.5%) 17 (53.1%) 11 (34.4%)
Dementia 5 (22.7%) 4 (18.2%) 13 (59.1%)
Pill CN 7 (18.9%) 21 (56.8%) 9 (24.3%)
MCI 4 (12.5%) 14 (43.8%) 14 (43.8%)
Dementia 4 (18.2%) 3 (13.6%) 15 (68.2%)
Infused CN 12 (32.4%) 23 (62.2%) 2 (5.4%)
MCI 9 (28.1%) 17 (53.1%) 6 (18.8%)
Dementia 6 (27.3%) 9 (40.9%) 7 (31.8%)
Diet/exercise CN 4 (10.8%) 18 (48.65%) 15 (40.5%)
MCI 4 (12.5%) 10 (31.3%) 18 (56.3%)
Dementia 3 (13.6%) 8 (36.4%) 11 (50.0%)
Supplement CN 4 (10.8%) 13 (35.1%) 20 (54.1%)
MCI 2 (6.3%) 9 (28.1%) 21 (65.6%)
Dementia 2 (9.1%) 8 (36.4%) 12 (54.6%)
MRI CN 7 (18.9%) 12 (32.4%) 18 (48.7%)
MCI 7 (21.9%) 8 (25.0%) 17 (53.1%)
Dementia 4 (18.2%) 9 (40.9%) 9 (40.9%)
PET scan CN 12 (32.4%) 11 (29.7%) 14 (37.8%)
MCI 8 (25.0%) 9 (28.1%) 15 (46.8%)
  Dementia 4 (18.2%) 9 (40.9%) 9 (40.9%)
Lumbar CN 24 (64.8%) 12 (32.4%) 1 (2.7%)
punctures MCI 15 (46.9%) 9 (28.1%) 8 (25.0%)
  Dementia 10 (45.4%) 9 (40.9%) 3 (13.6%)
Bleeding in brain or gut CN 30 (81.1%) 6 (16.2%) 1 (2.7%)
MCI 18 (56.3%) 11 (34.4%) 3 (9.4%)
Dementia 10 (45.5%) 9 (40.9%) 3 (13.6%)
Headache or nausea CN 15 (40.5%) 20 (54.1%) 2 (5.4%)
MCI 9 (28.1%) 16 (50.0%) 7 (21.9%)
Dementia 9 (40.9%) 8 (36.4%) 5 (22.7%)
  1. Values are shown as n (%)
  2. CN cognitively normal, MCI mild cognitive impairment, MRI magnetic resonance imaging, PET positron emission tomography